I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer

Summary

Data of 100 patients with locally advanced pancreatic cancer who received stereotactic radiotherapy or ct-guided radioactive 125I seed implantation in the multicenter of the research group from July 2019 to June 2021 were collected, as well as follow-up data.To evaluate the clinical efficacy of stereotactic radiotherapy and ct-guided 125I seed therapy with 3D printing template in pancreatic cancer;In addition, the local control rate and side effects of ct-guided radioactive 125I particles in the treatment of pancreatic cancer lesions were explored, and the efficacy and safety of different doses of stereotactic radiotherapy were determined.

Conditions

• Pancreatic Cancer Non-resectable
• Brachytherapy
• Radiotherapy

Interventions

RADIATION

Stereotactic Radiotherapy

GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10). Normal Tissue Limit: Reference to TG101 Report

RADIATION

3D-printing Template-assisted CT-guided I125 Seed Implantation

CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.

Sponsors & Collaborators

• Beijing 302 Hospital

  collaborator OTHER

• Guangxi Ruikang Hospital

  collaborator OTHER

• Tengzhou Central People's Hospital

  collaborator OTHER_GOV

• Peking University Third Hospital

  lead OTHER

Principal Investigators

• Junjie Wang, Chairman · Peking University Third Hospital

• Fei Xu · Peking University Third Hospital

• Xuezhang Duan, Director · Beijing 302 Hospital

• Kaixian Zhang, Director · Tengzhou Central People's Hospital

• Zuping Lian, Director · Guangxi Ruikang Hospital

• Zhe Ji · Peking University Third Hospital

• Jing Sun · Beijing 302 Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-06-11

Primary Completion

2021-05-31

Completion

2022-05-01

Countries

• China

Study Locations